The safety and side effects of monoclonal antibodies

Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412

Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164

Protein Therapeutics: A Summary and Pharmacological Classification

Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521

IL-23 promotes tumour incidence and growth

Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657

Management and Preparedness for Infusion and Hypersensitivity Reactions

Lenz, H.-J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-601 · Cited by 479

"Cytokine Storm" in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics

Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis

Cox, L., Platts-Mills, T. A. E., Finegold, I., Schwartz, L. B., Simons, F. E. R., & Wallace, D. V. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.09.032 · Cited by 295

Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy

Chung, C. H. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0012 · Cited by 278

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257

Development of therapeutic antibodies for the treatment of diseases

Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085

Regulation of tumour necrosis factor signalling: live or let die

Brenner, D., Blaser, H., & Mak, T. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3834 · Cited by 998

Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions

Kappelmann, N., Lewis, G., Dantzer, R., Jones, P. B., & Khandaker, G. M. (2018) · Molecular Psychiatry · doi:10.1038/mp.2016.167 · Cited by 659

Colorectal Cancer Immunotherapy: Options and Strategies

Johdi, N. A., & Sukor, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 452

Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab

Baumal, C. R., Spaide, R. F., Vajzovic, L., Freund, K. B., Walter, S. D., John, V., Rich, R., Chaudhry, N., Lakhanpal, R. R., Oellers, P. R., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.04.017 · Cited by 312

MERS-CoV spike protein: a key target for antivirals

Du, L., Yang, Y., Zhou, Y., Lu, L., Li, F., & Jiang, S. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1271415 · Cited by 301

The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies

Vaisman-Mentesh, A., Gutierrez-Gonzalez, M., DeKosky, B. J., & Wine, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01951 · Cited by 292

Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome

Staedtke, V., Bai, R.-Y., Kim, K., Darvas, M., Davila, M. L., Riggins, G. J., Rothman, P. B., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2018) · Nature · doi:10.1038/s41586-018-0774-y · Cited by 277

Voluntary activation of the sympathetic nervous system and attenuation of the innate immune response in humans

Kox, M., van Eijk, L. T., Zwaag, J., van den Wildenberg, J., Sweep, F. C. G. J., van der Hoeven, J. G., & Pickkers, P. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322174111 · Cited by 268

Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders

Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259

Diagnosis and management of anaphylaxis in precision medicine

Castells, M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.012 · Cited by 242

Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses

Baldo, B. (2013) · OncoImmunology · doi:10.4161/onci.26333 · Cited by 191

Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy

Mohanty, A., Uthaman, S., & Park, I.-K. (2020) · Molecules · doi:10.3390/molecules25194377 · Cited by 160

The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics

Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155

Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412

Römer, P. S., Berr, S., Avota, E., Na, S.-Y., Battaglia, M., ten Berge, I., Einsele, H., & Hünig, T. (2011) · Blood · doi:10.1182/blood-2010-12-319780 · Cited by 153

Prospects of brown seaweed polysaccharides (BSP) as prebiotics and potential immunomodulators

Okolie, C. L., C. K. Rajendran, S. R., Udenigwe, C. C., Aryee, A. N. A., & Mason, B. (2017) · Journal of Food Biochemistry · doi:10.1111/jfbc.12392 · Cited by 90

Engineered exosomes with a photoinducible protein delivery system enable CRISPR-Cas–based epigenome editing in Alzheimer’s disease

Han, J., Sul, J. H., Lee, J., Kim, E., Kim, H. K., Chae, M., Lim, J., Kim, J., Kim, C., Kim, J.-S., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi4830 · Cited by 87

Prostaglandin D 2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives

Marone, G., Galdiero, M. R., Pecoraro, A., Pucino, V., Criscuolo, G., Triassi, M., & Varricchi, G. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1555237 · Cited by 62

ADAP and SKAP55 deficiency suppresses PD‐1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti‐tumor immunotherapy

Li, C., Li, W., Xiao, J., Jiao, S., Teng, F., Xue, S., Zhang, C., Sheng, C., Leng, Q., Rudd, C. E., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404578 · Cited by 60

Targeting endothelial CD146 attenuates neuroinflammation by limiting lymphocyte extravasation to the CNS

Duan, H., Xing, S., Luo, Y., Feng, L., Gramaglia, I., Zhang, Y., Lu, D., Zeng, Q., Fan, K., Feng, J., et al. (2013) · Scientific Reports · doi:10.1038/srep01687 · Cited by 59

Molecular landscape of anti-drug antibodies reveals the mechanism of the immune response following treatment with TNFα antagonists

Vaisman-Mentesh, A., Rosenstein, S., Yavzori, M., Dror, Y., Fudim, E., Ungar, B., Kopylov, U., Picard, O., Kigel, A., Ben-Horin, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02921 · Cited by 54

Cell Contact–Dependent Priming and Fc Interaction with CD32+ Immune Cells Contribute to the TGN1412-Triggered Cytokine Response

Bartholomaeus, P., Semmler, L. Y., Bukur, T., Boisguerin, V., Römer, P. S., Tabares, P., Chuvpilo, S., Tyrsin, D. Y., Matskevich, A., Hengel, H., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302461 · Cited by 40

Immunological analysis of the murine anti‐CD3‐induced cytokine release syndrome model and therapeutic efficacy of anti‐cytokine antibodies

Nouveau, L., Buatois, V., Cons, L., Chatel, L., Pontini, G., Pleche, N., & Ferlin, W. G. (2021) · European Journal of Immunology · doi:10.1002/eji.202149181 · Cited by 25

Production of recombinant immunotherapeutics for anticancer treatment: The role of bioengineering

Pranchevicius, M.-C. S., & Vieira, T. R. (2013) · Bioengineered · doi:10.4161/bioe.24666 · Cited by 24

Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction

Tavori, H., Melone, M., & Rashid, S. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.954551 · Cited by 21

Modifications of IL-6 by Hypochlorous Acids: Effects on Receptor Binding

Robins, L. I., Keim, E. K., Robins, D. B., Edgar, J. S., Meschke, J. S., Gafken, P. R., & Williams, J. F. (2021) · ACS Omega · doi:10.1021/acsomega.1c05297 · Cited by 12

Therapeutic Monoclonal Antibodies for Metabolic Disorders: Major Advancements and Future Perspectives

Jamadade, P., Nupur, N., Maharana, K. C., & Singh, S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01228-0 · Cited by 11

Therapeutic Antibody-Induced Vascular Toxicity Due to Off-Target Activation of Nitric Oxide in Cynomolgus Monkeys

Pai, R., Ma, N., Connor, A. V., Danilenko, D. M., Tarrant, J. M., Salvail, D., Wong, L., Hartley, D. P., Misner, D., Stefanich, E., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw037 · Cited by 9

Prevention and inhibition of adverse humoral immune response to gene therapy mediated by adeno-associated virus (AAV) vector

Meliani, A. (2026) · doi:10.70675/83ee599czfe90z44e6za201z0938409e1748